Zacks Research Weighs in on CRISPR Therapeutics AG’s FY2026 Earnings (NASDAQ:CRSP)
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Research analysts at Zacks Research issued their FY2026 earnings estimates for CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Zacks Research analyst R. Department anticipates that the company will earn ($3.91) per share for the year. The consensus estimate for […]
More Stories
Democratic Rep. Haley Stevens Endorses GOP’s Mike Rogers in Michigan Senate Race
By Tom Gantert Rep. Haley Stevens (D-Mich.) endorsed Republican Mike Rogers in the state’s U.S. Senate race, in a video...
Investors Look Past Profits as Big Tech Burns Cash Amid Heavy AI Spending
By Panos Mourdoukoutas Microsoft, Alphabet, and Amazon reported strong earnings last week, yet Wall Street wasn’t impressed. Shares of all...
France’s Far-Left Protests on Halloween Descend Into Violence as Unrest Spreads Across Europe
By Etienne Fauchaire PARIS—Tens of thousands of left-wing demonstrators marched along the eastern edge of Paris on Saturday, in a...
Judge Dismisses Trump’s Defamation Lawsuit Against Wall Street Journal Publisher
By Tom Gantert A federal judge on Oct. 31 dismissed President Donald Trump’s defamation lawsuit against The Wall Street Journal’s...
Cybersecurity Researchers Link North Korea to $6.4 Billion Binance Hack
By Ryan Morgan Private blockchain analysis companies TRM Labs and Chainalysis have both assessed that North Korean state-backed hackers were...
US Approves Possible $2.1 Billion Sale of 500 Patriot Missiles to Ukraine
By Kimberly Hayek The State Department announced Oct. 30 that it has approved a possible sale of 500 Patriot Advanced...